Literature DB >> 17440098

Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth.

Yiting Cao1, Pierre Sonveaux, Shanling Liu, Yulin Zhao, Jing Mi, Bryan M Clary, Chuan-Yuan Li, Christopher D Kontos, Mark W Dewhirst.   

Abstract

Angiopoietin-2 (Ang-2) is a conditional antagonist and agonist for the endothelium-specific Tie-2 receptor. Although endogenous Ang-2 cooperates with vascular endothelial growth factor (VEGF) to protect tumor endothelial cells, the effect on tumor vasculature of high levels of exogenous Ang-2 with different levels of VEGF has not been studied in detail. Here, we report that systemic overexpression of Ang-2 leads to unexpected massive tumor vessel regression within 24 h, even without concomitant inhibition of VEGF. By impairing pericyte coverage of the tumor vasculature, Ang-2 destabilizes the tumor vascular bed while improving perfusion in surviving tumor vessels. Ang-2 overexpression transiently exacerbates tumor hypoxia without affecting ATP levels. Although sustained systemic Ang-2 overexpression does not affect tumor hypoxia and proliferation, it significantly inhibits tumor angiogenesis, promotes tumor apoptosis, and suppresses tumor growth. The similar antitumoral, antiangiogenic efficacy of systemic overexpression of Ang-2, soluble VEGF receptor-1, and the combination of both suggests that concomitant VEGF inhibition is not required for Ang-2-induced tumor vessel regression and growth delay. This study shows the important roles of Ang-2-induced pericyte dropout during tumor vessel regression. It also reveals that elevated Ang-2 levels have profound pleiotropic effects on tumor vessel structure, perfusion, oxygenation, and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17440098     DOI: 10.1158/0008-5472.CAN-06-4056

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  A simplified synthesis of the hypoxia imaging agent 2-(2-Nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-[(18)F]pentafluoropropyl)-acetamide ([18F]EF5).

Authors:  Satish K Chitneni; Gerald T Bida; Mark W Dewhirst; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2012-06-22       Impact factor: 2.408

2.  Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas.

Authors:  Sung-Suk Chae; Walid S Kamoun; Christian T Farrar; Nathaniel D Kirkpatrick; Elisabeth Niemeyer; Annemarie M A de Graaf; A Gregory Sorensen; Lance L Munn; Rakesh K Jain; Dai Fukumura
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 3.  Blood vessel maturation, vascular phenotype and angiogenic potential in malignant melanoma: one step forward for overcoming anti-angiogenic drug resistance?

Authors:  Iris Helfrich; Dirk Schadendorf
Journal:  Mol Oncol       Date:  2011-02-03       Impact factor: 6.603

4.  Tumor cells upregulate normoxic HIF-1α in response to doxorubicin.

Authors:  Yiting Cao; Joseph M Eble; Ejung Moon; Hong Yuan; Douglas H Weitzel; Chelsea D Landon; Charleen Yu-Chih Nien; Gabi Hanna; Jeremy N Rich; James M Provenzale; Mark W Dewhirst
Journal:  Cancer Res       Date:  2013-08-19       Impact factor: 12.701

Review 5.  Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.

Authors:  Hellmut G Augustin; Gou Young Koh; Gavin Thurston; Kari Alitalo
Journal:  Nat Rev Mol Cell Biol       Date:  2009-03       Impact factor: 94.444

6.  Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer.

Authors:  Lee W Jones; Benjamin L Viglianti; Jessica A Tashjian; Sejal M Kothadia; Stephen T Keir; Stephen J Freedland; Michael Q Potter; Eui Jung Moon; Thies Schroeder; James E Herndon; Mark W Dewhirst
Journal:  J Appl Physiol (1985)       Date:  2009-12-03

Review 7.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

Review 8.  Angiopoietin-2: development of inhibitors for cancer therapy.

Authors:  Bo Hu; Shi-Yuan Cheng
Journal:  Curr Oncol Rep       Date:  2009-03       Impact factor: 5.075

9.  Circulating IGF-1 deficiency exacerbates hypertension-induced microvascular rarefaction in the mouse hippocampus and retrosplenial cortex: implications for cerebromicrovascular and brain aging.

Authors:  Stefano Tarantini; Zsuzsanna Tucsek; M Noa Valcarcel-Ares; Peter Toth; Tripti Gautam; Cory B Giles; Praveen Ballabh; Jeanne Y Wei; Jonathan D Wren; Nicole M Ashpole; William E Sonntag; Zoltan Ungvari; Anna Csiszar
Journal:  Age (Dordr)       Date:  2016-09-09

10.  Characterization of TEM1/endosialin in human and murine brain tumors.

Authors:  Eleanor B Carson-Walter; Bethany N Winans; Melissa C Whiteman; Yang Liu; Sally Jarvela; Hannu Haapasalo; Betty M Tyler; David L Huso; Mahlon D Johnson; Kevin A Walter
Journal:  BMC Cancer       Date:  2009-11-30       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.